Chelohart
CardiovascularAlso known as: Heart peptide complex
Mechanism
An oral peptide complex derived from cardiac tissue. It normalizes cardiomyocyte (heart muscle cell) metabolism and supports cardiac function. Used as an oral bioregulator for cardiovascular health in aging populations in Russian clinical practice.
Technical detail
Peptide complex isolated from animal cardiac tissue, containing short peptides targeting cardiomyocytes. Proposed mechanism: modulates expression of genes involved in cardiomyocyte energy metabolism (mitochondrial respiratory chain complexes, creatine kinase), calcium handling (SERCA2a, ryanodine receptor), and structural proteins (troponin, myosin heavy chain). In aged animal models, improved left ventricular ejection fraction and reduced cardiomyocyte apoptosis. Russian clinical data report improvements in exercise tolerance and ECG parameters in elderly patients with chronic heart failure. Part of Cytomax oral bioregulator series.
Effects
## Detailed Effects — Chelohart ### Cardiovascular System [Tier 3] - Tripeptide bioregulator (Glu-Asp-Gly) from the Khavinson series, designed to target cardiac muscle cells (cardiomyocytes). - Proposed mechanism: penetrates cardiomyocyte cell membranes and interacts with DNA promoter regions to upregulate genes involved in cardiac contractility, energy metabolism, and stress resistance. - In vitro studies from the St. Petersburg Institute of Bioregulation and Gerontology report: restoration of protein synthesis in aged/stressed cardiomyocyte cultures, normalization of gene expression patterns related to mitochondrial function and calcium handling. - Proposed effects include: improved myocardial contractility, normalization of cardiac rhythm, enhanced resistance to ischemic stress, and improved endothelial function of coronary vessels. - Animal studies (primarily from Russian institutes): improved cardiac function parameters in aged animals, reduced infarct size in ischemia-reperfusion models. ### Autonomic Nervous System [Tier 3] - Proposed normalization of sympatho-vagal balance through improved cardiac function and baroreceptor sensitivity. - Some practitioner reports of improved heart rate variability (HRV) metrics during bioregulator courses. ### Cellular & Mitochondrial [Tier 3] - Proposed restoration of mitochondrial function in cardiomyocytes — improved oxidative phosphorylation efficiency, reduced ROS production. - Geroprotective (anti-aging) effects on cardiac tissue proposed through modulation of p53, Bcl-2, and telomere-associated gene expression.
Practitioner Guide
## Practitioner Guide — Chelohart ### Clinical Context - Chelohart is a cardiac bioregulator peptide from the Khavinson/St. Petersburg Institute series. - Not FDA-approved. Not available through Western compounding pharmacies. - Used clinically in Russia and some Eastern European countries as part of bioregulator protocols for age-related cardiac decline. - Available internationally as sublingual tablets or capsules from specialized peptide suppliers. ### Dosing Protocols (Practitioner Consensus) - **Sublingual tablets**: 1-2 tablets under the tongue, 1-3 times daily, 15-20 minutes before meals. - **Capsules**: 1-2 capsules daily with water, 15-20 minutes before meals. - **Standard course**: 10-30 days. Repeat courses every 3-6 months. - **Loading protocol** (intensive): 2 capsules BID x 10 days, then 1 capsule daily x 20 days. ### Stacking with Other Bioregulators - **Ventfort** (vascular bioregulator) + Chelohart = cardiovascular combination for both heart and vessels. - **Vilon** (immune bioregulator) + Chelohart = cardiac support with immune enhancement. - **Endoluten** (pineal bioregulator) + Chelohart = circadian rhythm normalization + cardiac support. - Bioregulator practitioners typically run 2-3 bioregulators simultaneously in 30-day courses, repeated every 3-6 months. ### Who Uses It - Patients with age-related cardiac decline (reduced exercise tolerance, mild heart failure symptoms). - Athletes seeking cardiac optimization and recovery support. - Longevity-focused patients doing comprehensive bioregulator programs. - Post-MI patients (as adjunct to standard cardiac medications — not a replacement). ### Storage - Room temperature (15-25°C). Protect from moisture and light. - Shelf life typically 2-3 years for capsules/tablets. ### Monitoring - HRV monitoring before and during course (wearable devices or clinic-based). - NT-proBNP levels if assessing cardiac stress. - Subjective exercise tolerance and recovery metrics. ### Key Caveat - Evidence is almost entirely Tier 3. No Western RCTs. No FDA review. - Should NOT replace evidence-based cardiac medications (ACEi, ARBs, beta-blockers, statins, etc.). - Use as an adjunct or for optimization in patients already on appropriate standard therapy.
Research Summary
## Research Summary — Chelohart ### Tier 1: Randomized Controlled Trials - No Western RCTs available. No publications in PubMed-indexed journals with RCT design for Chelohart specifically. ### Tier 2: Systematic Reviews & Preclinical Studies - Khavinson VK et al. (multiple publications, Bulletin of Experimental Biology and Medicine): in vitro and animal studies demonstrating tripeptide bioregulators interact with specific DNA sequences and modulate gene expression in target tissues. Chelohart specifically showed upregulation of cardiac contractility genes and cardioprotective effects in cell cultures. - The broader bioregulator peptide program (Khavinson Institute) has published over 200 papers, but most are in Russian-language journals or lower-impact international journals. ### Tier 3: Case Reports & Practitioner Protocols - Russian clinical experience spanning 20+ years in gerontology clinics. - Practitioner reports of improved HRV, exercise tolerance, and subjective energy in patients on Chelohart courses. - Commonly combined with Ventfort for comprehensive cardiovascular bioregulation. - The Khavinson bioregulator approach treats these as gene-regulatory agents that restore youthful gene expression patterns in aging tissues. ### Gaps - No double-blind, placebo-controlled RCTs published in English-language peer-reviewed journals. - No pharmacokinetic data — bioavailability, half-life, and tissue distribution not characterized by Western standards. - Mechanism of DNA interaction is proposed but not independently validated. - No comparative studies against established cardiac therapies. ### Active Trials - No registered clinical trials on ClinicalTrials.gov or EU Clinical Trials Register for Chelohart. - The St. Petersburg Institute continues to publish preclinical and clinical observational data.